Moody Aldrich Partners LLC Has $6.19 Million Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Moody Aldrich Partners LLC lowered its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 46.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 54,169 shares of the company's stock after selling 46,117 shares during the quarter. Moody Aldrich Partners LLC's holdings in Vaxcyte were worth $6,190,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Riverview Trust Co bought a new stake in Vaxcyte during the 3rd quarter worth about $27,000. Blue Trust Inc. grew its stake in shares of Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company's stock valued at $42,000 after purchasing an additional 93 shares during the last quarter. Fifth Third Bancorp acquired a new stake in shares of Vaxcyte in the second quarter valued at approximately $35,000. Fidelis Capital Partners LLC bought a new position in Vaxcyte in the 1st quarter worth approximately $37,000. Finally, J.Safra Asset Management Corp raised its position in Vaxcyte by 649.4% in the 2nd quarter. J.Safra Asset Management Corp now owns 607 shares of the company's stock worth $46,000 after purchasing an additional 526 shares during the last quarter. Institutional investors own 96.78% of the company's stock.

Insider Buying and Selling

In other Vaxcyte news, SVP Elvia Cowan sold 5,000 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $107.67, for a total value of $538,350.00. Following the completion of the sale, the senior vice president now directly owns 12,723 shares in the company, valued at $1,369,885.41. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Grant Pickering sold 15,000 shares of the firm's stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $78.98, for a total transaction of $1,184,700.00. Following the sale, the chief executive officer now directly owns 478,888 shares in the company, valued at $37,822,574.24. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Elvia Cowan sold 5,000 shares of the business's stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $107.67, for a total transaction of $538,350.00. Following the completion of the sale, the senior vice president now directly owns 12,723 shares in the company, valued at $1,369,885.41. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 92,098 shares of company stock valued at $9,937,773. 3.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

PCVX has been the subject of several research reports. Leerink Partners lifted their target price on Vaxcyte from $106.00 to $153.00 and gave the company an "outperform" rating in a research note on Tuesday, September 3rd. Mizuho boosted their price objective on Vaxcyte from $113.00 to $163.00 and gave the stock an "outperform" rating in a report on Tuesday, September 10th. Bank of America raised their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the company a "buy" rating in a research note on Wednesday, September 4th. Jefferies Financial Group boosted their price target on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a "buy" rating in a research note on Tuesday, September 3rd. Finally, Needham & Company LLC raised their price objective on shares of Vaxcyte from $95.00 to $140.00 and gave the company a "buy" rating in a research note on Tuesday, September 3rd. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vaxcyte presently has a consensus rating of "Buy" and a consensus target price of $147.50.

Vaxcyte Stock Performance

Shares of NASDAQ:PCVX traded up $0.18 during mid-day trading on Thursday, reaching $112.32. The stock had a trading volume of 474,825 shares, compared to its average volume of 673,833. The firm has a 50 day simple moving average of $104.73 and a two-hundred day simple moving average of $83.63. Vaxcyte, Inc. has a twelve month low of $45.61 and a twelve month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.04. During the same quarter last year, the business earned ($0.70) earnings per share. As a group, sell-side analysts forecast that Vaxcyte, Inc. will post -4.33 earnings per share for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.